As one BPCIA case came to a close in May, another got underway. On May 1, 2023, Amgen filed a complaint in the District of New Jersey, accusing Sandoz of infringing patents that relate.
/PRNewswire/ Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S..
16.08.2022 - DGAP-News: Formycon AG / Key word(s): Study results/Study Formycon s Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study 16.08.2022 / 07:30 CET/CEST The issuer is solely responsible . Seite 1
Samsung, Biogen get US green light for biosimilar to blockbuster Roche drug biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.